2026 Annual Meeting | Industry Therapeutic Update from SpringWorks: Clinical Evidence and the Role of Neurologists in Caring for Patients Living With NF1-PN

Date Sunday 04/19/26

Time 11:45 AM - 12:45 PM CDT Add To Calendar

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Justin T. Jordan, MD, MPH, FAAN

Topic(s) Neuro-oncology

Learning Objectives An interactive session focused on Neurofibromatosis Type 1-associated Plexiform Neurofibromas (NF1-PN), the critical role of neurologists in patient care, and strategies to optimize their involvement in co-management and as prescribers of targeted therapies. This program will explore the disease state and address key unmet medical needs, supported by patient case studies that highlight real-world clinical decision-making and outcomes.

CME Available No CME available

Event Timeline
11:45 AM - 12:45 PM CDT	Speaker	Industry Therapeutic Update from SpringWorks: Clinical Evidence and the Role of Neurologists in Caring for Patients Living With NF1-PN

Faculty Disclosures
Justin T. Jordan, MD, MPH, FAAN	Dr. Jordan has received personal compensation for serving as an employee of City of Beverly. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Genesis HR Solutions. An immediate family member of Dr. Jordan has received personal compensation for serving as an employee of Children's Hospital. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Shepherd Therapeutics. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Jordan has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Springworks Therapeutics. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for AstraZeneca. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Continental Casualty Company. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for HennLesperance. Dr. Jordan has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Rhoades McKee. Dr. Jordan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Wheeler Trigg O'Donnell. Dr. Jordan has or had stock in Navio Theragnostics. An immediate family member of Dr. Jordan has or had stock in OldGate.Dr. Jordan has or had stock in Shepherd Therapeutics.Dr. Jordan has or had stock in Khora TX. The institution of Dr. Jordan has received research support from NIH. The institution of Dr. Jordan has received research support from Department of Defense. The institution of Dr. Jordan has received research support from PCORI. Dr. Jordan has received publishing royalties from a publication relating to health care. Dr. Jordan has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��